197369-14-5

Usage

Uses

Reagent used to prepare pharmaceutically active Benzodioxole derivatives.

Upstream product

• 326-59-0 benzo[1,3]dioxol-5-yl-acetic acid methyl ester 
• 62-23-7 4-nitro-benzoic acid 
• 379733-75-2 trans-7,8-dihydro-7-methyl-5-(4-nitrophenyl)-5H-[1,3]dioxolo[4,5-g][2]benzopyrane 
• 6974-61-4 β-oxy-α-(3',4'-methylenedioxyphenyl)propane 

Downstream Products

• 501328-35-4 5,8-dihydro-5-(4-nitrophenyl)-7H-[1,3]dioxolo[4,5-g][2]benzopyran-7-one 
• 1192235-04-3 6,7-methylenedioxy-1-(4-nitrophenyl)-2H-isoquinolin-3-one 
• 197368-49-3 BDZ-2 
• 717911-66-5 1-Methyl-3-{2-[6-(4-nitro-benzoyl)-benzo[1,3]dioxol-5-yl]-acetyl}-urea 
• 473451-62-6 1-[2-(4-nitrobenzyl)-4,5-methylenedioxyphenylacetyl]-3-methylurea 
• 473451-61-5 2-(4-nitrobenzyl)-4,5-methylenedioxyphenylacetic acid 

Relevant academic research and scientific papers

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS

Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereof

The invention relates to a method for the preparation of compound of formula (1). The invention further relates to the previously unknown compounds of formulas (5 and 6) as intermediates in the production of benzodiazepines of formula (1).

Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II

A series of 1,3-benzodioxoles (2-12) were synthesized and evaluated for their in vitro ability to inhibit the growth of three human tumor cell lines. No cytotoxic effects were noticed with any of the test compounds at a concentration of 10-4 M.

Synthesis and antitumor activity of 1,3-benzodioxole derivatives.

A series of 1,3-benzodioxoles (5-19) was synthesized and evaluated for their in vitro antitumor activity against human tumor cell lines. Some derivatives exhibited tumor growth inhibition activity. In particular, 6-(4-aminobenzoyl)-1,3-benzodioxole-5-acetic acid methyl ester 8, the most active compound of the series, possesses a significant growth inhibitory activity on 52 cell lines at concentrations ranging from 10(-7) to 10(-5) M.

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.

Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2,3- benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists

A group of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2,3- benzodiazepin-4-ones was synthesized and assayed for antagonism of rat brain α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors expressed in Xenopus oocytes. The benzodiazepinones inhibited AMPA-activated membrane current responses in a manner consistent with noncompetitive, allosteric inhibition of the receptor-channel complex. The most potent compound in the series was 1-(4-aminophenyl)-7,8-(methylenedioxy)-3,5- dihydro-4H-2,3-benzodiazepin-4-one (6), which had an IC50 of 2.7 μM. For comparison, the reference compound GYKI 52466 (2) had an IC50 of 6.9 μM. Compound 6 also had potent anticonvulsant activity in a mouse maximum electroshock-induced seizure (MES) assay: the ED50 was 2.8 mg/kg iv, whereas the ED50 for GYKI 52466 was 4.6 mg/kg iv. In contrast to a previous report, the 7,8-dimethoxy analogue of 6 was a low-potency AMPA antagonist (IC50 > 100 μM) and weak anticonvulsant (ED60 > 10 mg/kg iv). The benzodiazepinones described herein are potent noncompetitive AMPA receptor antagonists that could have therapeutic potential as anticonvulsants and neuroprotectants.